IP-6

product on market Capsule Wonder Laboratories Safety: 100/100
100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 100% of ingredients have research evidence
A Label Compliance Grade

What the Evidence Says

AI-generated · Qwen 3.6 · grounded in 1 source · methodology

Inositol Hexaphosphate is researched for its potential role in supporting cellular health and mineral balance. Current evidence for these specific effects is limited, though the ingredient is generally well-tolerated. This profile focuses on a single compound with a high safety rating.

AI-generated summary based on research evidence. Not medical advice.

Label

Product Label

Label for IP-6
Open Full PDF View on NIH DSLD →
Details

Label Data

2 Capsule(s)
Serving Size
120
Servings
Non-Nutrient/Non-Botanical
Product Type
100%
Evidence Coverage
Ingredients

Supplement Facts — Evidence Check

Market median: 550.0mg (217 products) 29 studies (A:0, B:5)

Other Ingredients

k-Gelatin Vegetable Cellulose Vegetable Magnesium Stearate Silica
Claims

Label Claims — Verification

Unverified All Other
Unverified Structure/Function
Info

Product Information

Directions for Use

Directions: As a dietary supplement, take 2 capsules twice daily, during or after meals.

Warnings & Precautions

Tamper evident: Do not use this product if imprinted foil seal under cap is broken or missing.

Keep out of reach of children.

Caution:If you are pregnant or nursing, consult your physician before taking this product.

Formulation Notes

Inositol hexaphosphate nutritionally supports a health immune system.

Mfg. in a FDA registered facility using Good Manufacturing Practices (GMPs)

Ip-6 is Inositol Hexaphosphate derived from rice bran produced by Tsuno Foods in Japan

Conforms to USP <2091> for weight. Meets USP <2040> disintegration for maximum bioavailability.

Inositol Hexaphosphate

Nutritionally supports a healthy immune system

Gluten free

Ko Kosher Service

Made in USA

Additional Information

Keep tightly closed Store at room temperature: 59 degrees-86 degrees F (15 degrees to 30 degrees C).

Formula 587

Ko Kosher Service

Metadata

Product Details

UPC / SKU0 99528 58724 7
DSLD Entry Date2021-11-19
Product TypeNon-Nutrient/Non-Botanical
FormCapsule
DSLD ID260798
Data Updated2026-04-11
Research

Research Evidence

46
Research Sources
55
Avg Quality
23
Meta Analysis
7
Systematic Review
7
Rct
4
Clinical Trial
2
Other
1
Guideline
1
Regulatory Source
A Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
A Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)
Meta Analysis The Cochrane database of systematic reviews 2025 PubMed DOI
B Phosphate binders for preventing and treating bone disease in chronic kidney disease patients
Meta Analysis The Cochrane database of systematic reviews 2011 PubMed DOI
B Calcium and phosphorus supplementation of human milk for preterm infants
Systematic Review The Cochrane database of systematic reviews 2017 PubMed DOI
B Radiographic and clinical outcomes of silicate-substituted calcium phosphate (SiCaP) bone grafts in spinal fusion: Systematic review and meta-analysis
Meta Analysis Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2020 PubMed DOI
B ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Calcium, phosphorus and magnesium.
Guideline Clinical nutrition (Edinburgh, Scotland) 2018 PubMed DOI
B Effect of different phosphate binders on fibroblast growth factor 23 levels in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials
Meta Analysis Annals of palliative medicine 2022 PubMed DOI
B Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia
Meta Analysis The Cochrane database of systematic reviews 2015 PubMed DOI
B The impact of phosphate lowering agents on clinical and laboratory outcomes in chronic kidney disease patients: a systematic review and meta-analysis of randomized controlled trials
Meta Analysis Journal of nephrology 2022 PubMed DOI
B Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: A systematic review and meta-analysis of randomized studies
Meta Analysis Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 2024 PubMed DOI
View all evidence for Phosphorus →
Compare

Similar Products

View all Phosphorus products →

This product page is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before taking any supplement.